Brian O’Roak uses genomic approaches to unlock the genetic basis of neurodevelopmental disorders such as autism and intellectual disability.
Brian O’Roak
Associate professor of molecular and medical genetics
Oregon Health and Science University
From this contributor
How I learned to stop worrying and love preprints
Preprints are gaining traction in biology, but some researchers have lingering concerns. Should they?
Burning debate: What’s the best way to nab real autism genes?
How to best use a large volume of data to discover new genetic risk factors for autism is a matter of intense debate, particularly in light of historical challenges.
Burning debate: What’s the best way to nab real autism genes?
By
Brian O’Roak
27 June 2017 | 9 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read